Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Influence of calcitonin treatment on the osteocalcin concentration in the algodystrophy of bone

  • 20 Accesses

  • 9 Citations


Algodystrophy (AD) attacks all tissues in the affected region and results in the rapid demineralization of bones. Osteocalcin (OC) and alkaline phosphatase (AP) are markers of bone turnover. Calcitonin is the treatment of choice of AD. Two groups of patients were studied: Group I (n=8)-acute stage of AD (before and during the calcitonin treatment), Group II (n=5)-late chronic stage of AD. In the acute stage of AD both OC level and AP activity were increased. They were normal in the chronic state of AD. During the calcitonin treatment OC level normalized after 14 days and then increased again. During the treatment, AP activity temporarily increased and then returned to the initial level. We confirm that an increased bone turnover is observed in the acute stage of AD. Discrepancy between OC level and AP activity reflects the local metabolic disturbances. Salmon calcitonin inhibits the algodystrophic process and probably contributes to the activation of the skeletal restoration.

This is a preview of subscription content, log in to check access.


  1. 1.

    Doury, P. Algodystrophy. Reflex sympathetic dystrophy syndrome. Clin Rheumatol, 1987, 7, 173–80.

  2. 2.

    Carlson, T., Jacobs, A.M. Reflex sympathetic dystrophy syndrome. J Foot Surg 1986, 25, 149–153.

  3. 3.

    Doury, P., Pattin, S., Eulry, F., Faquert, P., Granier, R., Graillard, J.F. L'algodystropiie du genou. A propos d'une série de 125 observations. Rev Rhum Mal Osteoartic 1987, 54, 655–659.

  4. 4.

    Reginster, J.Y., Gritten, C., Franchimont, P. L'olgodystrophie. Rev Méd Liège 1986, 41, 996–1003.

  5. 5.

    Renier, J.C., Basle, M., Arlet, J., Seret, P. L'os et le métabolisme phosphocalcique dans l'algodystrophie. Rev Rhum Mal Osteoartic 1983, 50, 23–31.

  6. 6.

    DeGuembecker, W., DeGuembecker, C., Duriez, R., Duriez, J. Apport de l'absorption photonique dans le diagnostic des algodystrophis décalcifiantes des pieds. Rev Rhum Mal Osteoartic 1982, 49, 887–890.

  7. 7.

    Krawzak, H.W., Lindecken, K.D., Beyer, H.K., Mayer, M. Quantifizierung von Mineralisationsprozessen bei posttraumatischer Algodystrophie mittels computerotomographischer Densitometrie. Z Orthop 1989, 127, 202–206.

  8. 8.

    Sarrat, P., Acquaviva, P.C., Laforgue, P., Zakarian, H., Lopez, M., Bouscarle, B. L'algodystrophie de la tête fémorale. Apport des nouvelles méthodes d'imagerie. J Radiol 1988, 69, 495–500.

  9. 9.

    Constantinesco, A., Brunot, B., Demangeat, J.L., Foucher, G., Farcot, J.M. Apport de la scintigraphie osseuse en trois phases au diagnostic précoce de l'algodystrophie. Ann Chir Main 1986, 5, 93–104.

  10. 10.

    Rutishauser, E., Vernet, A., Marabraud, A. L'ostéoporose posttraumatique. Etude histopathologique.Acta Chir Belg 1956 (Suppl I) 123–148.

  11. 11.

    Rohner, A., Contribution à l'étude histopatologique de la dystrophie de Sudeck. Ann Anat Pathol 1958, 3, 477–511.

  12. 12.

    Arlet, J., Ficat, P., Durroux, R., Girou de Gercourt, R. Histopathologie des lésions osseuses et cartilagineuses dans l'algodystrophie sympathique réflexe du genou. Rev Rhum Mal Osteoartic 1981, 48, 315–321.

  13. 13.

    Arlet, J., Ficat, P., Durroux, R., Theallier, J.P., Mazières, B., Bouteiller, G. Histopathologie des lésions osseuses dans 9 cas d'algodystrophie de la hanche. Rev Rheum Mal Osteoartic 1978, 45, 691–698.

  14. 14.

    Fournié, A., Demblans-Dechans, B., Fournié, B., Muller de la Caffinière, M.J. Algodystrophies et test à la calcitonine. Aperçus Physiopathologiques. Rev Rhum Mal Osteoartic 1982, 49, 879–882.

  15. 15.

    Garcia-Carrasco, M., Gruson, M., De Vernejoul, M.C., Denne, M.A., Miravet, L. Osteocalcin and bone morphometric parameters in adults without bone disease. Calcif Tissue Int 1988, 42, 13–17.

  16. 16.

    Register, T.C., Wuthier, R.E. Effect of vanadate, a potent alkaline phosphatase inhibitor, on45Ca and32P uptake by a matrix vasicle-enriched fractions from chicken epiphyseal cartilage. J Biol Chem 1984, 259, 3511–3518.

  17. 17.

    Chambers, T.J., Chambers, J.C., Symonds, J., Darby, J.A. The effect of human calcitonin on the cytoplasmic spreading of rat osteoclasts. J Clin Endocrinol Metab 1986, 63, 1080–1985.

  18. 18.

    Strettle, R.J., Bates, R.F.L., Buckley, G.A., Evidence for a direct anti-inflammatory action of calcitonin: inhibition of histamine-induced mouse pinnal oedema by porcine calcitonin. J Pharm Pharmacol 1980, 32, 192–195.

  19. 19.

    Ceserani, R. Calcitonin and prostaglandin system. Life Sci 1979, 25, 1851–1856.

  20. 20.

    Roth, A., Kolaric, K. Analgetic activity of calcitonin in patients with painful osteolytic metastases of breast cancer. Oncology 1986, 43, 283–287.

  21. 21.

    Nuti, R., Vattimo, A., Martini, G., Turchetti, V., Righi, G.A. Carbocalcitonin treatment in Sudeck's atrophy. Clin Orthop Rel Res 1987, 215, 217–222.

  22. 22.

    Breitenfelder, J. Zur Therapie des Sudecks-Syndroms. Therapiewoche 1979, 29, 6578–6587.

  23. 23.

    Baylink, D.J., Taylor, A.K., Johnston, P., Leuken, S., Linkhart, S.G. Update on osteocalcin assays. Calcif Tissue Int 1991, 49 (Suppl), A4, 13.

  24. 24.

    Riggs, B.L., Tsai, K-S, Mann, K.G. Effects of acute increases in bone matrix degradation on circulating levels of bone Gla protein. J Bone Miner Res 1986, 1, 539–542.

  25. 25.

    Einhorn, T.A., Vigorita, V.J., Aaron, A. Localization of Technetium-99m-methylene diphosphonate in bone using microautoradiography. J Orthop Res 1986, 4, 180–187.

  26. 26.

    Vattimo, A., Martini, G., Pisani, M. Bone uptake of99mTc-MDP in man: its relationship with local blood flow. J Nucl Med All Sci 1982, 26, 173–179.

  27. 27.

    Farley, J.R., Hall, S.L., Tarbaux, N.M. Calcitonin (but not calcitonin gene-related peptide) increases mouse bone cell proliferation in a dosedependent manner, and increases mouse bone formation, alone and in combination with fluoride. Calcif Tissue Int 1989, 45, 214–221.

  28. 28.

    Griffiths, J., Black, J. Separation and identification of alkaline phosphatase isoenzymes and isoforms in serum of healthy persons by isoelectric focusing. Clin Chem 1987, 33, 2171–2177.

  29. 29.

    Arlet, J., Ficat, P. Phlébographie transosseuse, pression intramédullaire et oxymétrie du sang osseux au cours des algodystrophies sympathiques réflexes. Rev Rhum Mal Osteoartic 1982, 49, 883–885.

  30. 30.

    Asherl, R., Blümel, G. Zum Krankheitsbild der Sudeck'schen Dystrophie. Fortschr Med 1981, 99, 712–720.

  31. 31.

    Bassett, C.A.L., Herrmann, I. Influence of oxygen concentration and mechanical factors on differentiation of connective tissue in vitro. Nature 1961, 160, 460–461.

  32. 32.

    Wimalawansa, S.J. Calcitonin: molecular biology, physiology, pathophysiology and its therapeutic uses. In: Bone regulatory factors. Editor: Pecile, A., de Bernard, B. 1990, pp. 121–60.

  33. 33.

    Taoussanis, K. Erfahrungsberich über die Behandlung des Sudeck-Syndroms mit Calcitonin. Med Welt 1981, 32, 1375–1377.

  34. 34.

    Renier, J.C., Moreau, R., Bernat, M., Basle, M., Jallet, P., Minier, J.F., Apport des explorations isotopiques dynamiques dans l'étude des algodystrophies. Rev Rhum Mal Osteoartic 1979, 46, 235–241.

  35. 35.

    Caniggia, A., Nuti, R., Galli, M., Loré, F., Turchetti, V., Righi, G.A., Effect of a long-term treatment with 1,25-dihydroxyvitamin D3 on osteocalcin in postmenopausal osteoporosis. Calcif Tissue Int 1986, 38, 328–332.

  36. 36.

    Pak, C.Y.C., Sakhaee, K., Gallagher, C., Parcel, C., Peterson, R., Zerwekh, J.E., Lemke, M., Britton, F., Hsu, M.-C., Adams, B. Attainment of therapeutic fluoride levels in serum without major side-effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis. J Bone Miner Res 1986, 1, 563–571.

  37. 37.

    Papapoulos, S.E., Frolich, M., Mudde, A.H., Harnick, H.I.J., vd Berg, H., Bijvoet, O.L.M. Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment. J Clin Endocinol Metab 1987, 65, 89–94.

  38. 38.

    Mizunashi, K., Furukawa, Y., Miura, R., Yumita, R., Yumita, S., Sohn, H.E. Yoshinaga, K. Effects of active vitamin D3 and parathyroid hormone on the serum osteocalcin in idiopathic hypoparathyroidism and pseudohypoparathyroidism. J Clin Invest 1988, 82, 861–865.

  39. 39.

    Longstreth, P.L., Malinak, L.R. Hydroxyproline and transient osteoporosis. Ann Intern Med 1972, 76, 833.

Download references

Author information

Correspondence to A. Sawicki.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sawicki, A., Szulc, P., Sobczyk, T. et al. Influence of calcitonin treatment on the osteocalcin concentration in the algodystrophy of bone. Clin Rheumatol 11, 346–350 (1992). https://doi.org/10.1007/BF02207191

Download citation

Key words

  • Algodystrophy
  • Osteocalcin
  • Alkaline phosphatase
  • Calcitonin Treatment